Detection of late-onset hypogonadism in men with chronic internal diseases by Pozarskis, Anatolijs & Lejnieks, Aivars
INTRODUCTION
In recent years, much attention has been paid to the repro-
ductive health of males of different age. An important as-
pect of male health is the impact of somatic diseases on
male gonadal function. Knowledge on the issue of male
late-onset hypogonadism, or LOH, is moving forward. It
has been shown that with age, the testosterone level gradu-
ally decreases even in completely healthy males (Reisman
et al., 2015). Moreover, this issue has hardly been studied in
the context of comorbidities.
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Late-onset hypogonadism (LOH) is a clinical and biochemical syndrome associated with age and
featured by typical symptoms and reduced blood testosterone level. Among males aged over
30 years, the incidence of androgen deficiency is 7 to 30%. The aim of this study was to investi-
gate the incidence of hypogonadism in patients aged over 40 years with an underlying condition
and/or a comorbidity, such as arterial hypertension, Chronic obstructive pulmonary disease
(COPD), metabolic syndrome, Type 2 of diabetes mellitus, dyslipidaemia, adiposity in various
General practice (GP) and physician-sexologists’ offices in Latvia, and to determine the influence
of chronic diseases on the development of hypogonadism. Males aged 39 years who turned to
family doctors at nine GP were offered to fill in Aging Male Study (AMS) questionnaires used for
the diagnostics of late-onset hypogonadism. Males aged 40 years who visited the office of the
physician sexologist Anatolijs Poþarskis were offered to fill in the same questionnaires. After com-
piling the data from AMS questionnaires, a group of males exhibiting signs of LOH were isolated
(in total 1222 persons). In these patients, we determined blood testosterone and sex-hormone
binding globulin (SHBG) levels. Chronic diseases were found in these men in data evaluation of
patient medical records, and after performing physical and laboratory examinations. Late-onset
hypogonadism was laboratory-diagnosed in 79% of patients with signs of late-onset
hypogonadism in accordance with the AMS questionnaires and with concomitant diseases and in
4.7% of patients with signs of late-onset hypogonadism in accordance with the AMS question-
naires and without the aforementioned concomitant diseases. Persons with arterial hypertension,
dyslipidaemia, adiposity, metabolic syndrome, COPD and Type 2 of diabetes mellitus had higher
chance of developing hypogonadism (p < 0.001). Arterial hypertension, dyslipidaemia, adiposity,
metabolic syndrome, COPD statistically significantly (p < 0.001) decreased the level of total tes-
tosterone by 0.47, 1.18, 0.36, 0.67, and 0.18 ng/ml, respectively, and decreased the level of free
testosterone by 2.52, 2.71, 1,69, 6.77, and 4.58 pg/ml, respectively. Type 2 diabetes mellitus had
no statistically significant effect on the level of total and free testosterone (p = 0.95, p = 0.10). The
most significant decrease in the level of testosterone was observed in cases of dyslipidemia,
COPD and metabolic syndrome. General physicians should pay special attention to patients with
this disease, as these patients belong to a group with a high risk of development of expressed
LOH syndrome.
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Testosterone fraction dynamics have been studied in detail
in the context of rather prevalent diseases, such as arterial
hypertension, diabetes mellitus, dyslipoproteinemia, and
metabolic syndrome (Lunenfeld et al., 2015). These dis-
eases are featured by rather unfavourable prognosis regard-
ing high risk of local vascular pathology, reduction of the
quality of life, and premature death. A pressing issue is the
dynamics of testosterone fractions in cases of chronic ob-
structive pulmonary disease (COPD) (Karacou et al., 2013;
Vertkin et al., 2013).
The aims of our study were: to determine the labora-
tory-confirmed LOH prevalence in patients with signs of
LOH in accordance with Aging Males Study questionnaire
data and arterial hypertension, adiposity, dyslipidaemia,
metabolic syndrome, Type 2 diabetes mellitus and COPD;
to determine the laboratory-confirmed LOH prevalence in
patients with signs of LOH in accordance with AMS ques-
tionnaire data and without the aforementioned diseases; to
determine the effect of the aforementioned chronic diseases
on the prospects for hypogonadism development, by study
of the effect of these diseases on the total and free testoster-
one levels in patients with signs of LOH in accordance with
AMS questionnaire data; and to develop recommendations
for general practitioners regarding LOH diagnostics in men
over 40 years of age.
MATERIALS AND METHODS
The cross-sectional study was based on survey of men using
the Aging Males’ Symptoms questionnaire, or AMS ques-
tionnaire, as well as on the assessment of the participants by
means of clinical and laboratory methods. The Aging
Males’ Symptoms questionnaire was recommended to be
used in LOH diagnostics by the International Society for the
Study of the Aging Male (ISSAM) (Morales and Lunenfeld,
2002). The AMS questionnaire was translated into Latvian
and Russian by ISSAM for use in the study. Males with age
over 40 years who were referred by general practitioners at
nine general practitioner’s offices in Latvia due to acute ill-
nesses, exacerbations of chronic disease, or for preventive
examinations, and who had agreed to take part in the study,
were offered to complete the AMS questionnaire. Males
over 40 years of age, who were referred to the physi-
cian-sexologist Anatolijs Poþarskis’ office, were offered to
complete the same questionnaire. After the analysis of the
AMS questionnaire data, a group of men with signs of LOH
was identified. These patients were offered further partici-
pate in the study for determination of blood testosterone and
sex hormone building globuline (SHBG) levels. SHBG
level should be determined to calculate the level of free tes-
tosterone by a special formula (Morales and Lunenfeld,
2002). Men’s medical records filled in by the general practi-
tioners were also assessed, and chronic diseases identified
in anamnesis of these patients were recorded. The following
data in participants’ medical records for the last six months
were also recorded: blood glucose, total cholesterol, triglyc-
erides, high-density lipoprotein (HDL), and low-density li-
poprotein (LDL) levels, and spirometry. If the data were
present in a medical record, they were used in our study; if
the data were not available, blood glucose, total cholesterol,
triglycerides, LDL, and HDL levels were determined in pa-
tients. Physical examinations were performed, and the fol-
lowing indicators were determined: arterial blood pressure
on both arms; height and weight, body mass index, and
waist circumference.
The study group was comprised of patients in whom LOH
had been established in accordance with the AMS question-
naire data, and the following diseases were identified (n =
820): arterial hypertension, dyslipidaemia, adiposity, meta-
bolic syndrome, Type 2 diabetes mellitus, and COPD with
or without medication.
The control group was comprised of patients in whom LOH
had been established in accordance with the AMS question-
naire data, and in whom arterial hypertension, dyslipid-
aemia, adiposity, metabolic syndrome, Type 2 diabetes
mellitus, and COPD had not been diagnosed (n = 402).
These patients do not use any medication to treat the above
diseases. We used the following diagnostic criteria of so-
matic pathologies.
Arterial hypertension. We used the currently available hy-
pertension classification system recommended by the Euro-
pean Society of Hypertension and the European Society of
Cardiology (Mancia et al., 2013), where the optimal blood
pressure (BP) level is considered < 120/80 mmHg; normal
BP: 120–129/80–84 mmHg; high normal BP:
130–139/85–89 mmHg; stage 1 hypertension:
140–159/90–99 mmHg; stage 2 hypertension:
160–179/100–109 mmHg; and stage 3 hypertension:
 180/ 110 mmHg. Depending on blood pressure level,
risk factors, asymptomatic organ impairment, and presence
of concomitant clinical pathology, arterial hypertension, pa-
tients were divided into four risk groups of complications:
low, moderate, high, and very high risk (Mancia et al.,
2013). The study included patients with high and very high
risk of complications.
Diabetes mellitus was diagnosed on the basis of the follow-
ing criteria: repeated measurements of fasting blood glucose
levels > 7.0 mmol/l (120 mg %) or > 11.1 mmol/l (200 mg
%) two hours after 75 g glucose load.
Obesity diagnosis was carried out in accordance with mod-
ern WHO classification principles based on the body mass
index (Anonymous, 2000). According to the body mass in-
dex, normal weight corresponds to 18.5–24.99 kg/m2, over-
weight – to 25–29.99 kg/m2, obesity – to 30–39.99 kg/m2,
severe obesity –  40 kg/m2.
Dyslipidaemia was determined according to the following
metabolic parameters: total cholesterol concentration > 5.0
mmol/l, triglyceride level > 1.7 mmol/l, HDL cholesterol
concentration < 1.0 mmol/l, and LDL cholesterol concentra-
tion > 3.0 mmol/l.
Metabolic syndrome was diagnosed if at least three of the
following criteria had been established (Alberti et al.,
25Proc. Latvian Acad. Sci., Section B, Vol. 73 (2019), No. 1.
2009): arterial hypertension (characteristic values of arterial
blood pressure > 130/85 mm/Hg, or patients with arterial
hypertension using antihypertensive medication); triglycer-
ides > 1.7 mmol/l, or medical treatment of hyper-
triglyceridemia; fasting blood glucose level > 5.6 mmol/l, or
medical treatment of hyperglycaemia; HDL level < 1.0
mmol/l; waist circumference 94 cm, which is a sign of ab-
dominal obesity.
Chronic obstructive pulmonary disease. Moderately se-
vere COPD was diagnosed according to the following crite-
ria: anamnesis data (long-term smoking period, or
long-term exposure to substances irritant to respiratory sys-
tem), complaints (dyspnoea at physical exertion of moder-
ate intensity, productive cough, periods with cough and
high temperature), physical examination (vesiculo-
tympanitic resonance to percussion, weakened respiration,
dry noise to auscultation), instrumental examination (mea-
surement of forced expiratory volume in one second
(FEV1) 50 to 80% of the normal at FEV1/FVC < 0.70, and
a bronchodilation test where after the inhalation of salbuta-
mol FEV1 increased on average by 7.6%, which is a sign of
an irreversible bronchial obstruction).
Laboratory diagnosis of LOH was established by means
of immunoenzymatic method using the Multiskan Plus pho-
tometer test system at wavelength 450 nm. During the di-
agnostics, total and free testosterone levels were established
and divided into three categories: “normal value”, “reduced
to the threshold level”, and “abnormally low”. Following
the recommendations of International Society of Andrology
(ISA), International Society for The Study of The Aging
Male (ISSAM) and European Urology Association (EAU)
guidelines in 2006 (the year when our study was started),
total and free testosterone levels are considered normal at
> 3.46 ng/ml and > 72.00 pg/ml, reduced to the threshold
level – 3.46–2.31 ng/ml and 65.00–72.00 pg/ml, and abnor-
mally low < 2.31 ng/ml and ~65.00 pg/ml, respectively
(Nieschlag et al., 2006).
Non-parametric (percentage and its 95% confidence inter-
val, cross-tabulation analysis) and parametric descriptive
statistical methods (minimum, maximum, average, standard
deviation, median) were used to describe the population.
The Kolmogorov-Smirnov test was used to determine the
normal distribution of parametric indicators. The condi-
tional odds ratio (OR) was calculated using binary logistic
regression to determine the independent influence of
chronic diseases and age on hypogonadism. Binary logistic
regression was also used to search for different associations
between AMS symptoms and hypogonadism. Linear regres-
sion was used to determine the independent influence of
chronic diseases and age on total and free testosterone lev-
els. To evaluate the significance of the differences between
two sets of data, the Student’s t-criterion was used. The dif-
ference between the parameters was considered to be statis-
tically significant, if the t-value is  2 (in this case p <
0.05). Student's t-criterion was used to identify significant
differences in quantitative parameters of investigated pro-
cesses. Statistical data processing was performed using
SPSS (Statistical Package for the Social Sciences) 20.0 soft-
ware. MS Excel was used to create figures. The results were
considered to be statistically significant if p < 0.05.
RESULTS
The study comprised 820 patients with chronic internal dis-
eases. The following somatic and cardiac pathologies were
recorded in patients: arterial hypertension in 320 cases
(39%), obesity in 407 cases (49.6%), Type 2 diabetes melli-
tus in 67 patients (8.2%), dyslipidaemia in 681 patients
(83%), metabolic syndrome in 139 patients (17%), and
COPD in 107 patients (13%). The patients were in the age
range of 40 to 70 years, and were distributed in the follow-
ing age-defined patient groups: 40–45 years of age (81 pa-
tient, or 9.9%), 46–50 years of age (93 patients, or 11.3%),
51–55 years of age (372 patients, or 45.4%), 56–60 years of
age (157 patients, or 19.2%), 61–65 years of age (85 pa-
tients, or 10.4%), and 66–70 years of age (32 patients, or
3.9%) (Table 1).
402 men without any observed chronic concomitant disease
were enrolled in the study. Male age characteristics were as
follows: 40–45 years of age — 49 patients, 46–50 years of
age — 51 patients, 50–55 years of age — 83 patients, 56–60
years of age — 68 patients, 61–65 years of age — 70 pa-
tients, and 66–70 years of age — 81 patients.
According to clinical and laboratory data, hypogonadism
was found in 669 patients (54.7% of 1222 study partici-
pants). In patient groups with chronic comorbidities, hypo-
gonadism was found in 650 patients (79% of 820 study par-
ticipants). It was found in men without concomitant
diseases in 19 cases (4.7% of 402 participants in the group).
The prevalence of hypogonadism was statistically signifi-
cantly higher in the patient group with concomitant diseases
(p < 0.05).
The relationship between hypogonadism and chronic dis-
eases and age was investigated using single and multiple
factor analysis. The obtained results are shown in Table 2.
Persons with dyslipidaemia, adiposity, arterial hypertension,
metabolic syndrome, COPD and Type 2 diabetes mellitus
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T a b l e 1
AGE AND CLINICAL CHARACTERISTICS OF PATIENTS EN-
ROLLED IN THE STUDY
Age
(years)
AH ADPS DM Dyslp. COPD MS Total
40–45 30 45 2 54 12 33 176
46–50 52 65 14 97 10 25 263
51–55 40 48 9 102 24 39 262
56–60 44 76 15 147 16 31 329
61–65 58 79 14 140 21 5 317
66–70 96 94 13 141 24 6 374
AH, arterial hypertension; ADPS, adiposity; DM, diabetes mellitus;
Dyslp., dyslipidaemia; ED, erectile dysfunction; COPD, chronic obstruc-
tive pulmonary disease; MS; metabolic syndrome
had higher chance of developing hypogonadism (p < 0.001
in cases of dyslipidaemia, adiposity, arterial hypertension,
metabolic syndrome, and COPD, and p = 0.03 for diabetes
mellitus).
Association between age hypogonadism was also statisti-
cally significant (p < 0.001). Regardless of whether a man
had one of the chronic diseases, with an increase in age by
one year, the chances for a patient to develop hypogona-
dism increased by 1.13-fold, or by 13%.
The study found that the dyslipidaemia and COPD in-
creased the odds of developing hypogonadism (15.80- and
24.40-fold, respectively).
Using single and multiple factor analysis, the relationship
between total testosterone and chronic diseases and age was
determined (Table 3). Dyslipidaemia, adiposity, arterial hy-
pertension, metabolic syndrome and COPD was statistically
significantly (p < 0.001) associated with decreased level of
total testosterone. Type 2 diabetes mellitus had no statisti-
cally significant association with the level of total testoster-
one (p = 0.95).
Age also had an important role in reducing the level of total
testosterone. An increase of age by one year was associated
with decrease of the level of total testosterone by 0.03 units
(p < 0.001).
Dyslipidaemia and COPD were associated with decreased
level of total testosterone, regardless of other diseases and
age; presence of these diseases decreased the level of total
testosterone by 1.18 units.
The relationship between free testosterone and chronic dis-
eases and age is represented in Table 4. Dyslipidaemia, adi-
posity, arterial hypertension, metabolic syndrome and
COPD were statistically significantly (p < 0.001) associated
with decreased levels of free testosterone. Type 2 diabetes
mellitus was associated with decreased level of free testos-
terone by 1.92 units, but this indicator is not statistically
significant. Since one-factor analysis of the influence of
Type 2 diabetes mellitus on testosterone level showed lack
of statistical significance, Type 2 diabetes mellitus was not
further included in the multiple factor analysis model.
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T a b l e 2
SINGLE AND MULTIPLE FACTOR ANALYSIS OF THE RELATIONSHIP BETWEEN HYPOGONADISM AND CHRONIC DISEASES AND AGE IN
COMPARISON TO THE CONTROL GROUP
Independent characteristic mOR 95 % CI p cOR 95 % CI p
Dyslipidaemia 16.90 12.72–22.46 < 0.001 15.80 10.64–23.46 < 0.001
Adiposity 6.81 5.06–9.16 < 0.001 2.75 1.80–4.20 < 0.001
Arterial hypertension 6.08 4.39–8.43 < 0.001 3.68 2.34–5.78 < 0.001
Metabolic syndrome 8.99 5.01–16.10 < 0.001 4.66 2.33–9.32 < 0.001
COPD 3.98 2.39–6.62 < 0.001 24.40 11.83–50.34 < 0.001
Type 2 diabetes mellitus 2.03 1.18–3.50 0.01 1.47 1.24–1.92 0.03
Age 1.07 1.05–1.08 < 0.001 1.13 1.11–1.16 < 0.001
mOR, marginal odds ratio; cOR, conditional odds ratio; CI, confidence interval; p, level of significance; n, absolute number
T a b l e 3




95 % CI p Regression coeffi-
cient (conditioinal)*
95 % CI p
Dyslipidaemia – 1.64 – 1.53;
– 1.75
< 0.001 – 1.18 – 1.06;
– 1.30
< 0.001
Adiposity – 1.12 – 0.97;
– 1.26
< 0.001 – 0.36 – 0.24;
– 0.48
< 0.001
Arterial hypertension – 1.10 – 0.94;
–1.25
< 0.001 – 0.47 – 0.35;
– 0.59
< 0.001
Metabolic syndrome – 1.18 – 0.96;
– 1.40
< 0.001 – 0.67 – 0.50;
– 0.85
< 0.001
COPD – 1.00 – 0.75;
– 1.25
< 0.001 – 1.18 – 1.01;
– 1.36
< 0.001
Type 2 diabetes mellitus – 0.56 – 0.25;
– 0.88
0.001 0.007 – 0.22;
0.23
0.95
Age – 0.03 – 0.03;
– 0.04
< 0.001 – 0.03 – 0.03;
– 0.04
< 0.001
* The following factors were analysed: other investigated diseases, patient’s age.
Men’s age also had an important role in reducing the level
of free testosterone. An increase by one year of age was as-
sociated with decrease of the level of free testosterone by
0.34 units (p < 0.001).
DISCUSSION
With age, a man’s body undergoes changes that lead to de-
crease in concentration of testosterone: decrease in the num-
ber of testosterone-synthesising Leydig cells in testes, de-
crease in the density of luteinising hormone receptors,
impairments in the controlling communication of the hypo-
thalamic-pituitary system, the enzyme that ensures testoster-
one metabolic synthesis pathway, and decrease in concen-
tration and activity of this enzyme. With the reduction of
testosterone level, chronic diseases start to develop
(Scweiger et al., 1999; Jockenhovel, 2004; Isidori et al.,
2005; Lester and Mason, 2015). On the other hand, chronic
diseases can cause testosterone deficiency, or speed up its
development. For example, in patients with visceral adipos-
ity, fat cells synthesise biologically active substances,
which, being involved in metabolic processes, reduce tes-
tosterone synthesis as a result (Butrova, 1999; Poþarskis
and Çrenpreiss, 2010). In men with reduced libido or erec-
tile dysfunction, the frequency of sexual intercourse is re-
duced, which, in turn, increases the testosterone deficiency
even more. This forms a vicious circle: testosterone defi-
ciency causes chronic concomitant diseases, and concomi-
tant diseases increase the testosterone deficiency even more.
Arterial hypertension was established in 26% of the partici-
pants (n = 1222) and 39% of the subjects with concomitant
diseases (n = 820) in our study. LOH was found in patients
with hypertension more frequently than in normotensive pa-
tients. Men with arterial hypertension had 3.68-fold higher
odds of developing hypogonadism compared to men with-
out this condition. Regardless of other diseases and men’s
age, arterial hypertension decreased the level of both total
and free testosterone by 0.47 and 2.52 units, respectively.
Although the literature data provide evidence on the con-
nection of LOH in patients with metabolic syndrome and its
components, i.e. adiposity or dyslipidaemia (Blaya et al.,
2016), as well as the connection of testosterone deficiency
with cardiovascular diseases and mortality risk (Lester and
Mason, 2015), there have been too limited data on the
prevalence of hypogonadism in patients with arterial hyper-
tension until now. The European Male Ageing Study
(launched in 2003) investigated health, chronic diseases,
and the level of sex steroids in over 3000 men in the age
group of 40 to 79 years. Arterial hypertension was diag-
nosed in 28% of the study participants (both hypogonadal
and eugonadal). In patients with hypogonadism, systolic
blood pressure was statistically significantly increased, but
diastolic did not change (Tajar et al., 2012). Similar results
were obtained in the Massachusetts Male Aging study in the
USA. In that study, arterial hypertension was found in 36%
of the patients. It was demonstrated that in patients with hy-
pogonadism both systolic and diastolic blood pressure was
higher than in patients with a normal testosterone level
(Feldman et al., 1994). In our study, arterial hypertension
was observed almost as frequently as in the studies de-
scribed above. Our study results are in line with the studies
described above, as testosterone deficiency was more fre-
quently observed in patients with arterial hypertension com-
pared with those without hypertension.
Adiposity was diagnosed in 33% of participants (n = 1222)
and in 49.6% of participants with concomitant diseases (n =
820). LOH was observed more frequently in patients with
adiposity than in those with normal weight, as described in
the literature. Several studies have demonstrated a direct
correlation of testosterone deficiency with adiposity. For
example, European Male Ageing Study demonstrated that
patients with LOH had an increased body mass index and/or
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T a b l e 4






95 % CI p Regression coeffi-
cient (condi-tioinal)*
95 % CI p
Dyslipidaemia –5.86 –4.87;
–6.85





< 0.001 –1.69 –0.57;
–2.81
< 0.001
Arterial hypertension –5.34 –4.20;
–6.49
< 0.001 –2.52 –1.41;
–3.64
< 0.001
Metabolic syndrome –7.08 –5.49;
–8.67





< 0.001 –4.58 –2.97;
–6.19
< 0.001
Type 2 diabetes mellitus –1.92 –4.20;
–0.36
0.10 – – –
Age –0.30 –0.25;
–0.36
< 0.001 –0.34 –0.28;
–0.39
< 0.001
* The following factors were analysed: other investigated diseases, patient’s age.
waist circumference. In addition, a direct correlation be-
tween body weight and testosterone indicators was shown.
A decrease of body weight by more than 10% was associ-
ated with increase of total testosterone level by 2.9 nmol/l
(0.84 ng/ml) on average; when body weight increased by
more than 10%, total testosterone level decreased by
2.4 nmol/l (0.69 ng/ml) on average. If body weight differ-
ences were in the range of up to 10%, differences in testos-
terone level were not statistically significant (Lester and
Mason, 2015). The relationship of LOH with adiposity is
also described in other publications. On the one hand, tes-
tosterone deficiency causes fat accumulation; on the other
hand, fat cells produce active substances that reduce the
synthesis of testosterone (Butrova, 1999). As a result of this
bilateral process, health condition deteriorates progres-
sively, and adiposity complications occur: metabolic syn-
drome, Type 2 diabetes mellitus, arterial hypertension,
coronary and heart disease (Phillips et al., 1994; Simon et
al., 1997; Ohlsson et al., 2011). In our study we concluded
that men with adiposity have a 2.75-fold higher chance of
suffering from hypogonadism compared to men who do not
have adiposity (p < 0.001). We also observed that, regard-
less of other diseases and age, adiposity statistically signifi-
cantly (p < 0.001) decreased the level of both total testoster-
one by 0.36 ng/ml, and free testosterone by 1.69 pg/ml.
These results are similar to those in the European Male
Ageing Study, where a direct correlation between body
weight and testosterone levels was found.
The proportion of adiposity in men aged 40–70 (33%) in
our study was similar to data from clinical trials in Europe
and in the United States (Lester and Mason, 2015, Feldman
et al., 1994). In these studies, obesity in men aged 40 years
and older has been found in 23.9% and 40% of the cases,
respectively. According to Eurostat data, in the European
Union countries the proportion of adults (aged 18 years and
over) who were considered to be overweight varied in 2014
between 53.6% in the Netherlands and 67.5% in Croatia for
men. Adiposity generally increased with age. The age group
18 to 24 years had the lowest share of the overweight popu-
lation, while the 65 to 74 year group had the highest share
(Anonymous, 2014). The large prevalence of obesity in Lat-
via may be explained by the fact that “Western” eating hab-
its are spreading increasingly in Latvia: more fast food is
used.
Type 2 diabetes mellitus was diagnosed in 5.5 % of the
study participants (both with and without comorbidities, n =
1222) and in 8.2% of participants with concomitant diseases
(n = 820). Our data are similar to the findings of the Euro-
pean Male Ageing Study, where Type 2 diabetes was found
in 6.6% of men over 40 years of age. We diagnosed LOH in
67.2% of the patients with Type 2 diabetes mellitus. A sta-
tistically significant association of Type 2 diabetes mellitus
with hypogonadism was observed (p = 0.03); Type 2 diabe-
tes mellitus increased the odds of developing hypogona-
dism by approximately 1.5 times, but no statistically signifi-
cant effect of Type 2 diabetes mellitus on the levels of total
and free testosterone (p = 0.10, p = 0.95) was found. How-
ever, the high proportion of LOH in Type 2 diabetes melli-
tus patients is in line with the literature data mentioning that
testosterone deficiency increases the risk of development of
metabolic syndrome and Type 2 diabetes mellitus (Simon et
al., 1997; Ohlsson et al., 2011). In a study in which
103 male patients with Type 2 diabetes mellitus were in-
volved, Dhindsa with co-authors found that hypogonadism
occurred in 33% of men. A statistically significant correla-
tion between body mass index and free testosterone level
was shown; the higher the BMI, the lower the free testoster-
one level (Dhindsa et al., 2004). Chandel with co-authors
determined the concentration of testosterone in 38 young
men (mean age 26.45 ± 0.89 years) with Type 1 diabetes
mellitus and 24 young men (mean age 27.87 ± 0.97 years)
with Type 2 diabetes mellitus. Hypogonadism was estab-
lished in 58 % of patients with Type 2 diabetes mellitus. In
Type 1 diabetes mellitus patients, hypogonadism occurred
in 8% of the cases only. The authors concluded that the
level of testosterone was lower in Type 2 diabetes mellitus
patients compared to Type 1 diabetes mellitus patients, and
that the prevalence of hypogonadism was very high in Type
2 diabetes mellitus patients (Chandel et al., 2008). Similar
results were obtained by Tomar with co-authors in a study
comprised of 15 patients with Type 1 diabetes mellitus pa-
tients and 50 patients with Type 2 diabetes mellitus. The
levels of testosterone and free testosterone in patients with
Type 1 diabetes mellitus were within the normal range,
while in patients with Type 2 diabetes mellitus, total testos-
terone level was decreased in 48% of cases, and free testos-
terone level in 26% of the cases. Consequently, hypogona-
dism was common in Type 2 diabetes mellitus patients, but
not in men with Type 1 diabetes mellitus (Tomar et al.,
2006). The fact that our study revealed no statistically sig-
nificant influence of Type 2 diabetes mellitus on total and
free testosterone levels, which is different from other stud-
ies conducted elsewhere in the world, can be explained by
the relatively small number of Type 2 diabetes mellitus pa-
tients enrolled in the study.
Dyslipidaemia was diagnosed in 55.7% of the study partici-
pants (both with and without comorbidities, n = 1222), and
in 83% of men with concomitant diseases (n = 820). The
observed prevalence of dyslipidaemia was similar to the
data described in literature. In the Massachusetts Male Ag-
ing Study, dyslipidaemia was diagnosed in 55% of men
aged 40 to 79 years. In the European Male Ageing Study,
dyslipidaemia was not investigated separately; a group of
patients with “One or more concomitant diseases”, includ-
ing coronary heart disease, arterial hypertension, dyslipidae-
mia and others, was distinguished. Various studies showed
a direct correlation of hypogonadism with dyslipidaemia.
For example, the Telecom Study and the Rancho Bernardo
Study showed that lower level of testosterone was associ-
ated with higher LDL and triglyceride levels, and lower
HDL level (Simon et al., 1997; Laughlin et al., 2008).
Other authors also noted the relationship between dyslipi-
daemia, metabolic syndrome, and LOH in their publica-
tions, and testosterone replacement therapy (TRT) was rec-
ommended as an effective method of treatment of metabolic
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syndrome and its components (Winter et al., 2014). In some
smaller studies, a correlation between dyslipidaemia and
LOH was not shown. For example, in a study that enrolled
247 patients with LOH (average age was 75.8 years), al-
though a trend toward lower levels of testosterone was
found in patients with cardiovascular risk factors, this dif-
ference was not statistically significant (Ponholzer et al.,
2010). Perhaps this was due to the small number of partici-
pants in the study. Our study results are in line with those of
large studies that showed dyslipidaemia to be more frequent
in men with hypogonadism than in eugonadal patients. We
established that, regardless of other chronic diseases and
men’s age, patients with dyslipidaemia had a 15.80-fold
higher chance of suffering from hypogonadism compared to
men who did not have dyslipidaemia (p < 0.001). We also
showed that, regardless of other diseases and age, dyslipi-
daemia decreased the levels of both total and free testoster-
one by 1.18 and 2.71 units, respectively. Such a significant
role of dyslipidaemia can be explained by its involvement
in the pathogenesis of several pathological processes, for
example, in the development of metabolic syndrome, or en-
dothelial dysfunction.
We recorded metabolic syndrome in 11.4% of the study
participants (n = 1222), and in 17% of participants with
concomitant diseases (n = 820). Metabolic syndrome was
found more frequently in patients with reduced testosterone
levels than in eugonadal men, as described in the literature.
Wide epidemiological studies enrolling men over 40 years
of age, such as the Massachusetts Male Aging Study and
European Male Ageing Study, increased prevalence of
metabolic syndrome in men with testosterone deficiency
was shown (Feldman et al., 1994; Lester and Mason, 2015).
Meta-analysis of 20 studies indicated that metabolic syn-
drome was associated with LOH, and TRT had a positive
effect on metabolic control and central adiposity (Corona et
al., 2011). Our study revealed that metabolic syndrome de-
creased the free testosterone level by 6.77 pg/ml, more than
by other diseases studied. This can be explained by the fact
that several pathogenetic mechanisms causing hypogona-
dism are enabled in patients with metabolic syndrome:
overweight and lipid metabolism disorders, and glucose me-
tabolism disorders. The correlation of these factors with tes-
tosterone deficiency is widely described in literature (Phil-
lips et al., 1994; Simon et al., 1997; Laughlin et al., 2008;
Ohlsson et al., 2011). Consequently, patients with meta-
bolic syndrome should be vigilant early, already at 40 years
of age, concerning the possible development of LOH.
COPD was diagnosed in 8.8% of the study participants (n =
1222) and in 13% of men with concomitant diseases (n =
820). In patients with COPD, the testosterone level was sta-
tistically significantly lower than in patients without con-
comitant diseases. Compared to other diseases studied,
COPD was found to increase the odds of development of
hypogonadism to the greatest extent (24.4-fold); the total
testosterone level decreased along with dyslipidaemia to the
greatest extent (by 1.18 units) and was the second important
cause of decrease of free testosterone level after metabolic
syndrome. COPD reduced the free testosterone level by
4.58 units. Similarly, in a study of testosterone level in
69 patients with COPD and a control group, the testosterone
level in patients with COPD was statistically significantly
lower (Karakou et al., 2013). In addition, a direct correla-
tion between testosterone level and the severity of COPD
has been observed (Vertkin, 2013). In a study comprising
70 patients with COPD, prevalent erectile dysfunction and
lower testosterone level were observed, but the difference in
testosterone level was not statistically significant compared
with the control group (Kahraman et al., 2013). Meta-
analysis of 2918 patients in nine studies involving patients
with COPD, testosterone concentration was lower than in
control groups. However, these studies did not involve a
large number of participants (Atlantis et al., 2013). In a re-
view of studies (Balasubramanian and Naing, 2012), hypo-
gonadism was found in COPD patients in 22–69 % of cases,
and was associated with other systemic problems: osteopo-
rosis, depression, and muscle weakness. Such a significant
importance of COPD in developing hypogonadism and de-
creasing testosterone levels may be due to hypoxia caused
by this disease, which in turn interferes with the supply of
oxygen to both the testicles and the CNS and harms the syn-
thesis of testosterone. However, some recent studies, ac-
cording to the author’s data, provide controversial informa-
tion on the aforementioned facts. The difference in results
may be related to the small number of participants in the
study, and the selection criteria. Data on the efficacy of
TRT in COPD patients are controversial and need to be fur-
ther explored (Balasubramanian and Naing, 2012). Analysis
of 140 COPD patients with an average age of 67.4 ±
10.1 years showed that hypogonadism occurred in 58.6% of
men and there was a correlation between testosterone level
and the severity of COPD (Mousavi et al., 2012). In large
epidemiological studies involving men over 40 years of age,
such as Massachusetts Male Aging Study and the European
Male Ageing Study, the prevalence of COPD and its asso-
ciation with testosterone deficiency have not been studied.
CONCLUSIONS
Arterial hypertension, dyslipidaemia, obesity, metabolic
syndrome, COPD, and Type 2 diabetes mellitus increase the
odds of developing hypogonadism. In patients with this dis-
ease serum testosterone levels were found to be lower in
comparison to the control group. In addition, the most sig-
nificant decrease was observed in cases of dyslipidaemia,
metabolic syndrome, and COPD. Dyslipidaemia and COPD
decreased total testosterone concentration by 1.18 ng/ml
(p < 0.001), while the decrease in free testosterone levels
was most commonly caused by metabolic syndrome and
COPD: by 6.77 and 4.58 pg/ml, respectively. Patients aged
40 years or over, having arterial hypertension, or adiposity,
or dyslipidaemia, or metabolic syndrome, or Type 2 diabe-
tes mellitus, or COPD, are recommended for screening of
gonadal function condition, in order to prescribe corrective
testosterone replacement therapy if necessary. General phy-
sicians should pay special attention to patients with meta-
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bolic syndrome, dyslipidaemia, and COPD, as these patients
belong to a group with a high risk of development of ex-
pressed LOH syndrome.
The authors declare that there is no conflict of interests re-
garding the publication of this paper.
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VÇLÎNÂ HIPOGONÂDISMA ATTÎSTÎBAS ÎPATNÎBAS VÎRIEÐIEM AR IEKÐÍÎGÂM SLIMÎBÂM
Vçlîns hipogonâdisms (VH) ir klînisks un bioíîmisks sindroms, kas asociçjas ar vecumu un raksturojams ar tipiskiem simptomiem un
samazinâtu testosterona lîmeni asinîs. Vîrieðiem pçc 30 gadu vecuma androgçnu deficîta sastopamîba ir no 7 lîdz 30%. Pçtîjuma mçríis bija
izpçtît VH izplatîbu pacientiem ar paralçli un/vai vienlaikus noritoðu patoloìiju: arteriâla hipertensija, adipozitâte, hroniska obstruktîva
plauðu slimîba (HOPS), metaboliskais sindroms, 2. tipa cukura diabçts, dislipidçmija daþâdâs ìimenes ârstu un seksologu praksçs un ðo
slimîbu ietekmi uz hipogonâdisma attîstîbu. Vîrieðiem pçc 40 gadu vecuma tika piedâvâts aizpildît “Vîrieða novecoðanas anketas” (AMS –
Aging Male Study questionnaires) deviòâs ìimenes ârstu praksçs un viena ârsta seksologa praksç. Apkopjot AMS anketas datus, tika
izdalîta vîrieðu grupa, kurai konstatçtas VH pazîmes (n = 1222). Ðiem pacientiem tika noteikts asinîs testosterona un dzimumhormonu
saistoðâ globulîna (DHSG) lîmeni. Izmantojot ierakstus ambulatorâs kartçs un fizikâlu izmeklçðanu, tika izpçtîtas hroniskas iekðíîgas
slimîbas ðai pacientu grupai. Pacientiem ar VH pazîmçm pçc AMS anketas datiem un ar blakusslimîbâm VH laboratoriski diagnosticçts
79% gadîjumu. Pacientiem ar VH pazîmçm pçc AMS anketas datiem un bez blakusslimîbâm VH diagnosticçts 4,7% gadîjumu. Arteriâlâ
hipertensija, dislipidçmija, aptaukoðanâs, metaboliskais sindroms, HOPS un 2. tipa cukura diabçts palielina hipogonâdisma attîstîbas
izredzes (p < 0,001). Arteriâla hipertensija, dislipidçmija, adipozitâte, metaboliskais sindroms, HOPS statistiski nozîmîgi (p < 0,001)
pazemina kopçja testosterona lîmeni attiecîgi par 0,47, 1,18, 0,36, 0,67 un 0,18 ng/ml un brîva testosterona lîmeni — attiecîgi par 2,52,
2,71, 1,69, 6,77 un 4,58 pg/ml. 2 tipa cukura diabçtam nav konstatçta statistiski ticama ietekme uz kopçja un brîva testosterona lîmeni (p =
0,95, p = 0,10). Visnozîmîgâkâ testosterona lîmeòa pazeminâðanâs tika novçrota dislipidçmijas, metaboliskâ sindroma un HOPS gadîjumos.
Ìimenes ârstam savâ darbâ îpaða uzmanîba jâpievçrð pacientiem ar ðîm slimîbâm, jo ðâdi pacienti ietilpst vçlîna hipogonâdisma sindroma
attîstîbas augsta riska grupâ.
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